Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer
- PMID: 38346070
- PMCID: PMC10861092
- DOI: 10.1371/journal.pone.0298125
Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer
Abstract
The tumor heterogeneity is an important cause of clinical therapy failure and yields distinct prognosis in ovarian cancer (OV). Using the advantages of integrated single cell RNA sequencing (scRNA-seq) and bulk data to decode tumor heterogeneity remains largely unexplored. Four public datasets were enrolled in this study, including E-MTAB-8107, TCGA-OV, GSE63885, and GSE26193 cohorts. Random forest algorithm was employed to construct a multi-gene prognostic panel and further evaluated by receiver operator characteristic (ROC), calibration curve, and Cox regression. Subsequently, molecular characteristics were deciphered, and treatments strategies were explored to deliver precise therapy. The landscape of cell subpopulations and functional characteristics, as well as the dynamic of macrophage cells were detailly depicted at single cell level, and then screened prognostic candidate genes. Based on the expression of candidate genes, a stable and robust cell characterized gene associated prognosis signature (CCIS) was developed, which harbored excellent performance at prognosis assessment and patient stratification. The ROC and calibration curves, and Cox regression analysis elucidated CCIS could serve as serve as an independent factor for predicting prognosis. Moreover, a promising clinical tool nomogram was also constructed according to stage and CCIS. Through comprehensive investigations, patients in low-risk group were charactered by favorable prognosis, elevated genomic variations, higher immune cell infiltrations, and superior antigen presentation. For individualized treatment, patients in low-risk group were inclined to better immunotherapy responses. This study dissected tumor heterogeneity and afforded a promising prognostic signature, which was conducive to facilitating clinical outcomes for patients with OV.
Copyright: © 2024 Ding et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures








Similar articles
-
Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.J Ovarian Res. 2022 Nov 23;15(1):123. doi: 10.1186/s13048-022-01059-0. J Ovarian Res. 2022. PMID: 36424614 Free PMC article.
-
CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.Front Immunol. 2023 Mar 31;14:1151109. doi: 10.3389/fimmu.2023.1151109. eCollection 2023. Front Immunol. 2023. PMID: 37063862 Free PMC article.
-
A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.J Ovarian Res. 2023 Sep 20;16(1):196. doi: 10.1186/s13048-023-01275-2. J Ovarian Res. 2023. PMID: 37730669 Free PMC article.
-
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022. Front Immunol. 2022. PMID: 36405735 Free PMC article.
-
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.BMC Cancer. 2021 Jul 27;21(1):858. doi: 10.1186/s12885-021-08611-z. BMC Cancer. 2021. PMID: 34315402 Free PMC article.
Cited by
-
Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation/immunity and patient outcome.Front Pharmacol. 2025 Feb 6;16:1500251. doi: 10.3389/fphar.2025.1500251. eCollection 2025. Front Pharmacol. 2025. PMID: 39981173 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical